REPLIGEN CORP
RGENNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for RGEN. That does not mean none is planned.
Get an email about RGEN's next catalysts
Track REPLIGEN (RGEN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (offering).See the timeline
1 upcoming, 1 past
Stock Offering
Repligen announced privately negotiated exchange and subscription agreements to issue $1.0 billion of 0.25% Convertible Senior Notes due 2031, partly exchanging ~$456.8M of its 1.00% 2028 Notes and raising ~$458.6M in cash. About $120M of proceeds will fund a share repurchase, with the remainder for working capital and potential acquisitions.
SourceHow RGEN's past catalysts played out
Market Overview
Stock performance and key metrics
Repligen Corporation is an American life sciences company that develops and manufactures products used in biological drug manufacturing. The company is headquartered in Waltham, Massachusetts, and is listed on the Nasdaq under the symbol RGEN.
WebsiteRG1068 (Synthetic Human Secretin)
Obsessive Compulsive Disorder (OCD)
Uridine
Bipolar Depression
Subcutaneous Secretin
Schizophrenia
RG2417
Bipolar I Depression
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
RG1068 (Synthetic Human Secretin) | Phase 3 | Obsessive Compulsive Disorder (OCD) | - | - |
Uridine | Phase 2 | Bipolar Depression | - | - |
Subcutaneous Secretin | Phase 2 | Schizophrenia | - | - |
RG2417 | Phase 2 | Bipolar I Depression | - | - |
Frequently asked questions
What is in REPLIGEN CORP's drug pipeline?→
CatalystAlert tracks 4 drug candidates in REPLIGEN CORP's (RGEN) pipeline across Phase 3, Phase 2. Its lead program is RG1068 (Synthetic Human Secretin) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is REPLIGEN CORP's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for REPLIGEN CORP (RGEN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RGEN biotech catalysts?→
Add RGEN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow REPLIGEN CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.